NCT03870919: Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

NCT03870919
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Serine-Threonine Kinase Inhibitor, Radiation Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient biopsy of the primary tumour must display at least 10% of cancer cells with ER++ staining; HER2+ is defined as IHC3+ or FISH/CISH
Exclusions: Patients with prior therapy for metastatic breast cancer (systemic or local)
https://ClinicalTrials.gov/show/NCT03870919

Comments are closed.

Up ↑